WINREVAIR™ (sotatercept-csrk) for injection 45 mg, 60 mg

Open Menu Close Menu

Search

Search WINREVAIR™ Information

To report a side effect or product quality complaint, call 1-800-672-6372

STELLAR study

The efficacy of WINREVAIR was evaluated in adult patients with PAH in STELLAR, a 24-week, global, double-blind, placebo-controlled, multicenter, parallel-group clinical trial.¹

Patients with PAH (WHO Group 1 FC II or III) Randomized to One of Two Treatments: Placebo + Stable Background Therapy or WINREVAIR (Starting Dose: 0.3 mg/kg) + Stable Background Therapy

^aAll patients were on stable doses of background therapy for PAH for ≥90 days before enrollment and continued receiving background therapy throughout the trial.^1,2

SC Q3W = subcutaneous every 3 weeks.

STELLAR excluded patients with human immunodeficiency virus (HIV)-associated PAH, PAH associated with portal hypertension, schistosomiasis-associated PAH, and pulmonary veno-occlusive disease.

Efficacy endpoints

Primary endpoint

Change from baseline in 6-minute walk distance (6MWD) at week 24

Selected secondary endpoints¹

Proportion of patients who improve from baseline by at least 1 WHO FC at week 24
Time to death from any cause or PAH clinical worsening event (TTDCW)
- These outcomes were captured until the last patient completed the week 24 visit and included death from any cause, worsening-related listing for lung and/or heart transplant, need to initiate rescue therapy with an approved PAH therapy or the need to increase the dose of infusion prostacyclin by ≥10%, need for atrial septostomy, PAH-specific hospitalization (≥24 hours), or deterioration of PAH (worsened WHO FC and decrease in 6MWD by ≥15% confirmed by two 6-minute walk tests at least 4 hours apart but no more than 1 week).
Change from baseline in pulmonary vascular resistance (PVR) at week 24
Change from baseline in N-terminal pro-B-type natriuretic peptide (NT-proBNP) at week 24

Back to top

Selected baseline characteristics

Mean time from PAH diagnosis to screening

8.8 years (range: 1.8 to 15.8 years)¹

Race and ethnicity

White/Caucasian: 89%
Black/African American: 2%
Asian: 2%

American Indian or Alaska Native: 0.3%
Native Hawaiian or other Pacific Islander: 0.3%
Missing/other races: 6%

WHO functional class at baseline

FC II: 49%
FC III: 51%

Sex

Female: 79%

Most common PAH etiologies

Idiopathic PAH: 59%
Heritable PAH: 18%
PAH associated with connective tissue diseases (CTD): 15%

Median age

48 years (range: 18 to 82 years)

Background PAH therapy

Triple therapy: 61%
Double therapy: 35%
Monotherapy: 4%
Prostacyclin infusions: 40%

Median weight

68 kg (range: 38 to 141 kg)

References:

Hoeper MM, Badesch DB, Ghofrani HA, et al; STELLAR Trial Investigators. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023;388(16):1478-1490.
Hoeper MM, Badesch DB, Ghofrani HA, et al; STELLAR Trial Investigators. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023;388(16) (suppl):S1-S69.

Navigate to:

FAQs

Primary endpoint data

Indication

WINREVAIR is an activin signaling inhibitor indicated for the treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events.

Selected Safety Information

Erythrocytosis: WINREVAIR may increase hemoglobin (Hgb). Severe erythrocytosis may increase the risk of thromboembolic events or hyperviscosity syndrome. Monitor Hgb before each dose for the first 5 doses, or longer if values are unstable, and periodically thereafter, to determine if dose adjustments are required.

Severe Thrombocytopenia: WINREVAIR may decrease platelet count. Severe thrombocytopenia may increase the risk of bleeding. Thrombocytopenia occurred more frequently in patients also receiving prostacyclin infusion. Do not initiate treatment if platelet count is <50,000/mm³. Monitor platelets before each dose for the first 5 doses, or longer if values are unstable, and periodically thereafter to determine whether dose adjustments are required.

Serious Bleeding: In clinical studies, serious bleeding (eg, gastrointestinal, intracranial hemorrhage) was reported in 4% of patients taking WINREVAIR and 1% of patients taking placebo. Patients with serious bleeding were more likely to be on prostacyclin background therapy and/or antithrombotic agents, or have low platelet counts. Advise patients about signs and symptoms of blood loss. Do not administer WINREVAIR if the patient is experiencing serious bleeding.

Embryo-Fetal Toxicity: WINREVAIR may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use an effective method of contraception during treatment with WINREVAIR and for at least 4 months after the final dose. Pregnancy testing is recommended for females of reproductive potential before starting WINREVAIR treatment.

Impaired Fertility: Based on findings in animals, WINREVAIR may impair female and male fertility. Advise patients on the potential effects on fertility.

Adverse Reactions: The most common adverse reactions occurring in the phase 3 clinical trial (≥10% for WINREVAIR and at least 5% more than placebo) were headache (24.5% vs 17.5%), epistaxis (22.1% vs 1.9%), rash (20.2% vs 8.1%), telangiectasia (16.6% vs 4.4%), diarrhea (15.3% vs 10.0%), dizziness (14.7% vs 6.2%), and erythema (13.5% vs 3.1%).

Lactation: Because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with WINREVAIR, and for 4 months after the final dose.

Before prescribing WINREVAIR, please read the accompanying Prescribing Information. The Patient Information and Instructions for Use (1-vial kit, 2-vial kit) also are available.

STELLAR study